CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY
Efficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen jo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2014-07-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/27 |
| _version_ | 1797198196007501824 |
|---|---|
| author | V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky |
| author_facet | V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky |
| author_sort | V. S. Shirinsky |
| collection | DOAJ |
| description | Efficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen joints, and slower ESR in fenofibrate group (n = 33) as compared with control group (n = 17). Frequency of EULAR and ACR20 responses was 4 times higher in fenofibrate group. Clinical effect was accompanied by decrease in serum immunological markers of atherosclerosis (IL-6 and CRP), diminished total cholesterol andtriglycerides. In summary, PPARα agonists may represent an example of a “hub” treatment for rheumatoid arthritis, with pleiotropic effects directed at inflammatory activity and increased risk of other comorbidites, including atherosclerosis. |
| first_indexed | 2024-03-08T05:52:07Z |
| format | Article |
| id | doaj.art-ec66ce617207447990c77f175285ec70 |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2024-04-24T06:56:01Z |
| publishDate | 2014-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-ec66ce617207447990c77f175285ec702024-04-22T13:07:32ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-01161718010.15789/1563-0625-2014-1-71-8027CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDYV. S. Shirinsky0O. A. Polovnikova1N. Yu. Kalinovskaya2I. V. Shirinsky3Research Institute of Clinical Immunology, Russian Academy of Medical Sciences, Siberian Branch, NovosibirskResearch Institute of Clinical Immunology, Russian Academy of Medical Sciences, Siberian Branch, NovosibirskResearch Institute of Clinical Immunology, Russian Academy of Medical Sciences, Siberian Branch, NovosibirskResearch Institute of Clinical Immunology, Russian Academy of Medical Sciences, Siberian Branch, NovosibirskEfficacy and pharmacodynamics of PPARα agonist fenofibrate have been assessed in a controlled study on patients with active rheumatoid arthritis (RA) receiving traditional DMARDs. After 12 weeks of treatment, we observed a significant drop of DAS28 scores, decrease in number of tender and swollen joints, and slower ESR in fenofibrate group (n = 33) as compared with control group (n = 17). Frequency of EULAR and ACR20 responses was 4 times higher in fenofibrate group. Clinical effect was accompanied by decrease in serum immunological markers of atherosclerosis (IL-6 and CRP), diminished total cholesterol andtriglycerides. In summary, PPARα agonists may represent an example of a “hub” treatment for rheumatoid arthritis, with pleiotropic effects directed at inflammatory activity and increased risk of other comorbidites, including atherosclerosis.https://www.mimmun.ru/mimmun/article/view/27autoimmune disordersrheumatoid arthritispparfenofibrate |
| spellingShingle | V. S. Shirinsky O. A. Polovnikova N. Yu. Kalinovskaya I. V. Shirinsky CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY Медицинская иммунология autoimmune disorders rheumatoid arthritis ppar fenofibrate |
| title | CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY |
| title_full | CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY |
| title_fullStr | CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY |
| title_full_unstemmed | CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY |
| title_short | CLINICAL EFFICACY AND SAFETY OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA AGONISTS IN RHEUMATOID ARTHRITIS: AN OPEN-LABEL CONTROLLED STUDY |
| title_sort | clinical efficacy and safety of peroxisome proliferator activated receptor alpha agonists in rheumatoid arthritis an open label controlled study |
| topic | autoimmune disorders rheumatoid arthritis ppar fenofibrate |
| url | https://www.mimmun.ru/mimmun/article/view/27 |
| work_keys_str_mv | AT vsshirinsky clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT oapolovnikova clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT nyukalinovskaya clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy AT ivshirinsky clinicalefficacyandsafetyofperoxisomeproliferatoractivatedreceptoralphaagonistsinrheumatoidarthritisanopenlabelcontrolledstudy |